Monitor for partnering announcements for IMM-529 and IMM-124E, which represent the primary valuation catalysts. The strategic reset to reduce R&D spend and focus on OTC sales growth should improve near-term cash runway.
Price Chart
Executive Summary
Immuron Ltd filed a 6-K furnishing a presentation from the Coffee Microcaps Conference. The presentation highlights FY26 financial results (global sales revenue A$7.7M, up 6% YoY; net loss A$(3.8)M, a A$1.4M improvement; cash A$9.0M) and a strategic reset to partner pipeline assets IMM-124E and IMM-529 for development and commercialization, aiming for profitability and reduced cash burn. An exclusive U.S. distribution agreement for ProIBS was executed in September 2026. The filing is a routine investor presentation with no new material financial disclosures beyond previously reported results.
Key Facts
- FY26 global sales revenue A$7.7M, up 6% YoY
- FY26 net loss A$(3.8)M, a A$1.4M improvement
- Cash A$9.0M as of 30 June 2026
- Strategic reset to partner IMM-124E and IMM-529 for development and commercialization
- Exclusive U.S. distribution agreement for ProIBS executed in September 2026
- FDA IND approved for IMM-529 Phase 2 study
- Lumanity peak U.S. sales estimate of US$102M for IMM-124E and US$400M for IMM-529
Financial Impact
FY26 global sales revenue A$7.7M (up 6% YoY); net loss A$(3.8)M (A$1.4M improvement); cash A$9.0M
Risk Factors
- No binding partnership agreements announced for pipeline assets
- Reliance on partnering model to fund clinical development
- Modest revenue base with net losses continuing
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-101907 |
| Document: ea0306168-6k_immuron.htm | 0001213900-26-101907 |
| Document: 0001213900-26-101907-index-headers.html | 0001213900-26-101907 |
| Document: 0001213900-26-101907-index.html | 0001213900-26-101907 |
| Document: 0001213900-26-101907.txt | 0001213900-26-101907 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $0.9300 | awaiting T+60 | — | $0.9300 (+0.00%) |
Oct 23, 2026 4d ago | 6-K | $0.9200 | awaiting T+60 | — | $0.9300 (+1.09%) |
Oct 23, 2026 4d ago | 424B5 | $0.9200 | awaiting T+60 | — | $0.9300 (+1.09%) |
Oct 21, 2026 6d ago | 6-K | $0.9490 | awaiting T+60 | — | $0.9300 (−2.00%) |
Oct 16, 2026 11d ago | 6-K | $0.9821 | awaiting T+60 | — | $0.9300 (−5.30%) |
Oct 13, 2026 14d ago | 6-K | $1.04 | awaiting T+60 | — | $0.9300 (−10.58%) |
Sep 24, 2026 4w ago | 20-F | $1.19 | awaiting T+60 | — | $0.9300 (−21.85%) |
Sep 24, 2026 4w ago | 6-K | $1.19 | awaiting T+60 | — | $0.9300 (−21.85%) |
Sep 21, 2026 5w ago | 6-K | $1.26 | awaiting T+60 | — | $0.9300 (−25.90%) |
Sep 4, 2026 7w ago | Press Release | $1.80 | awaiting T+60 | — | $0.9300 (−48.33%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers